Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06848894
NA

Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment

Sponsor: Beijing Tiantan Hospital

View on ClinicalTrials.gov

Summary

This study aims to explore the efficacy and safety of Human Urinary Kallidinogenase for acute ischemic stroke patients receiving intravenous thrombolysis and/or endovascular treatment.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1204

Start Date

2025-03

Completion Date

2027-12

Last Updated

2025-03-28

Healthy Volunteers

No

Interventions

DRUG

Human urinary kallidinogenase (HUK)

HUK (0.15 PNA) and sodium chloride injection (100ml), once per day

DRUG

Placebo

placebo (0 PNA) and sodium chloride injection (100ml), once per day

Locations (1)

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, China